8-K: Current report filing
Published on June 5, 2007
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 |
|
FORM
8-K
|
|
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
|
Date
of
Report (Date of earliest event reported): June 4,
2007
|
|
ACCESS
PHARMACEUTICALS, INC.
|
|
|
|
(Exact
name of registrant as specified in its charter)
|
|
Delaware
|
0-9314
|
83-0221517
|
|
|
|
|
|
(State
or other jurisdiction
of incorporation) |
(Commission
File Number) |
(IRS
Employer
Identification No.) |
|
2600
Stemmons Freeway, Suite 176
Dallas, Texas |
|
75207
|
|
|
|
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
Registrant's telephone number, including
area code:
|
(214)
905-5100
|
|
|
|
|
|
|
|
|
|
|
(Former
name or former address, if changed since last report)
|
|
Check the appropriate box below if
the
Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions
(see
General Instruction A.2. below):
|
|
/x/
|
Written communications pursuant to
Rule
425 under the Securities Act (17 CFR 230.425)
|
|
/ /
|
Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
/ /
|
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
/ /
|
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01. Other Events
On June 4, 2007, Access issued a press release announcing data
regarding Angiolix presented at ASCO Oncology Conference.
The full text of the press release is furnished
as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by
reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press
release issued by Access
Pharmaceuticals, Inc. and Somanta Pharmaceuticals, Inc. dated June 4, 2007.
|
SIGNATURES
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
ACCESS PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/ Stephen B. Thompson
|
|
|
|
|
|
|
|
|
Stephen B. Thompson
|
|
|
|
Vice President, Chief Financial
Officer
|
|
Date: June 4, 2007
Exhibit Index
Exhibit No. Description
99.1 Press
release issued
by Access Pharmaceuticals, Inc. and Somanta Pharmaceuticals, Inc. dated June
4,
2007.
|
|